My Canadian Pharmacy's News

My Canadian Pharmacy: Smoking and Erectile Function

It is well-known that smoking represents a social problem of society, both for smoker, and for non-smoking part presently. The first category torments itself with a question of the termination of smoking, the second tries to secure themselves against influence of the smokers. Certainly, smoking does harm to both a man’s, and female half of mankind, but this article will provide you information on how smoking influences an erectile function, how two concepts smoking and erection are connected.

Smoking Strikes Blow to Mankind

All know of harm caused by smoking, the erectile function also develops from this artful habit. However around the world about 15 billion cigarettes are smoked every day. According to the conducted researches in 2009 in the USA the share of smokers among adult population makes about 60,2% among the man’s population, and 21,7% among women. Addiction to cigarettes costs much to the owner of this harmful habit. Almost every third man of our country smokes, causing an irreparable loss to him health (lung cancer, bad erection) and to health of the relatives.


From 3 to 5 million, are a human tribute of death, for addiction to smoking. At such tendencies by 2020 annually about 10 million people in the world will die of smoking. The figure which turns out at calculation of all financial influences (a cigarette, a lighter, chewing gums) can discourage even the heaviest smokers who don’t even ask a question: how to leave off smoking and to begin to lead a healthy lifestyle. My Canadian Pharmacy claims that it is very important to keep a healthy lifestyle that’s why if you desire to give up smoking or increase your erection you are welcome on our website to order drugs necessary for these purposes realization.

The Smoke of Cigarettes Kills Man’s Erection

The tobacco smoke, contains about 5 thousand chemical compounds, 60 of which cause impotence:

  • hydrocyanic acid;
  • carboxylic acids;
  • carbon monoxide;
  • hydrogen nitride;
  • the diverse toxic substances which are harmful influencing man’s health.

Smoking and Erectile Function

The Ministry of Health was tired to repeat about harm of smoking long ago. Scientists-doctors are engaged in development of new preparations, psychologists write books about how to leave off smoking in a week, sorcerers apply miracles of traditional medicine. However, despite all efforts, the number of smokers every day become more and more increased. If you lose already the hope you may choose the remedies on the website – My Canadian Pharmacy to carry out the treatment.

Smoking is possible by the right to consider as the most terrible drug. So from heroin and other “heavy” drugs mortality is less many times. Availability and Cheapness of cigarettes have led to what the mankind has received most artfully and the enemy, dangerous to itself. Which is especially dangerous, negatively influencing an erection – killing the healthy future of mankind.

Smokers often are ill on lung cancer, chronic bronchitis, decrease of sexual capabilities is also observed. Smoking and erection have close connection. Smoking not negatively influences a condition of cardiovascular system. Change of erectile function at the smoker happens due to narrowing of basin vessels. The last is responsible for intake of blood in genital and on erectile function. Smoking leads also to the fact that walls of blood vessels of genital are corked, negatively affecting erectile function.


My Canadian Pharmacy: Deliberations about Impact of Palivizumab on Admission to the ICU for Respiratory Syncytial Virus Bronchiolitis

sRSV diseaseIn the present national surveillance survey, we compared PICU admissions and the need for mechanical ventilation for the treatment of RSV bronchiolitis between the following two consecutive seasons: before and after the introduction of palivizumab in Israel. Seventeen percent of the patients admitted to a PICU in both periods were candidates for RSV prophylaxis according to the AAP guidelines. For period 1, 13.3%; and for period 2, 9.7% (p < 0.01) were candidates for RSV prophylaxis according to the IMH recommendations. The difference in the rates associated with the AAP and the IMH guidelines is probably attributable to the broader criteria of the AAP guidelines.

The present study takes an alternative look at the epidemiology of severe RSV disease. It did not ask which patients were at greater risk of severe disease, but rather, among those with severe disease what risk factors were present. We sought to investigate the potential impact of palivizumab therapy on the burden of PICU admissions due to RSV infections. We evaluated the PICU admissions for RSV bronchiolitis with respect to the recognized risk factors associated with an increased severity of RSV disease, namely, prematurity and CLD. The study showed that the majority of children who were admitted to the PICU lacked these risk factors, probably because the majority of infants in the general population are not premature and do not have CLD.


My Canadian Pharmacy about Temporal Changes in Clinical Outcomes With ARDS

Acute lung injury Acute lung injury (ALI) and ARDS are common and lethal conditions. The spectrum of lung injury represented by ALI/ARDS affects approximately 150,000 people each year in the United States, although the number may be much higher.2 The mortality rate associated with ALI/ARDS depends on the underlying cause, varying from < 20% for traumatically injured patients to > 60% for sepsis-induced ALI/ARDS. Crude estimates of the health-care costs associated with ALI/ARDS may exceed $5 billion per year in the United States alone. Substantial efforts have been devoted to finding effective therapies and improving clinical outcomes, and to date we have had limited, if any, success.

In this issue of CHEST, Stapleton and colleagues provide an expanded report on ALI/ ARDS patients at the University of Washington, From these subjects, they report that the fatality rates of patients with ALI/ARDS have declined over time, with sepsis-related complications being the most common cause of death at nearly 50% and respiratory failure being a relatively uncommon cause of death at < 20%. Importantly, the reductions in patient fatalities are most apparent in patients with trauma-related ALI/ARDS, while patients with sepsis-related lung injury continue to experience the highest fatality rates. The proportion of deaths that occur within the first 3 days after contracting ALI/ARDS compared to those occurring later has not changed, yet it appears that death may be occurring more swiftly for the growing percentage of patients who have life support measures withdrawn.


Outcomes of Impact of Palivizumab on Admission to the ICU for Respiratory Syncytial Virus Bronchiolitis

bronchodilatorsOne hundred twenty-nine children were admitted to the 13 PICUs in Israel because of acute bronchiolitis during period 1 (from 2000 to 2001), and 167 children were admitted during period 2 (from 2001 to 2002). Of these patients, 105 children (81.4%) and 123 children (73.7%), respectively, were RSV-posi-tive. The remainder were RSV-negative, including two patients in period 1 and one patient in period 2 with unknown RSV status. There was no statistically significant difference between the periods for this factor (p = 0.127). An analysis of the seasonal distribution of PICU admissions for RSV bronchiolitis revealed that in both periods 75 to 85% of the RSV-positive patients were admitted to PICUs from December to February, and 100% were admitted from November to April. All of the patients with proven RSV-negative status were admitted to PICUs from November to March (approximately 10 cases per month). The data for period 2 are shown in Figure 1. Because our study focused on palivizumab prophylaxis (a specific monoclonal antibody against RSV), the non-RSV- positive patients (ie, those with RSV-negative and unknown status) were excluded from the analysis.


Investigation about Impact of Palivizumab on Admission to the ICU for Respiratory Syncytial Virus Bronchiolitis

RSV bronchiolitisThis prospective study was conducted in all 13 PICUs in Israel. The study sample included all patients who had been admitted to a PICU because of clinical symptoms indicative of acute bronchiolitis from November 2000 to April 2001 (period 1), the year before the IMH recommendations were issued, and from November 2001 to April 2002 (period 2), the year after they were issued. In the second season, palivizumab was available throughout the country and was administered in a hospital-based setting. Part of the data from the first period has already been published by our group.

Cases of RSV bronchiolitis in both periods were identified by the authors, by personal communication, or by weekly visits or phone calls with a senior staff member of every PICU in Israel during the RSV season. A detailed questionnaire was completed at each PICU admission for all patients with clinical symptoms of acute bronchiolitis cured by medicines of My Canadian Pharmacy. In addition, the PICU admission registries were examined periodically to prevent omissions or errors. The following characteristics were recorded: age; gender; gestational age; birth weight; perinatal medical history; medical treatment since discharge from the neonatal department; present medical treatment; presence of CLD; oxygen requirement prior to PICU admission; palivizumab prophylaxis; indication for PICU admission; medical treatment; RSV status; total number of days of PICU hospitalization; total number of days receiving mechanical ventilation; and death. RSV status was determined by nasopharyngeal aspirate and standard RSV enzyme immunoassay, as reported. CLD was defined as oxygen dependence at a gestational age of 36 weeks. Congenital heart disease was considered to be cyanotic when a right-to-left shunt was present, delivering deoxygenated blood from the right side of the heart into the arterial circulation.


My Canadian Pharmacy: Impact of Palivizumab on Admission to the ICU for Respiratory Syncytial Virus Bronchiolitis

Respiratory syncytial virusAlmost all children become infected with respiratory syncytial virus (RSV) within 2 years after birth. Although the infection usually presents as a mild upper respiratory tract disease, up to 1% of infected children require hospitalization. Overall, RSV accounts for 50 to 90% of all hospitalizations for bronchiolitis in children.2 In patients with a known underlying disease, such as chronic lung disease (CLD) or congenital heart disease, and in premature children, RSV bronchiolitis can quickly become a severe, life-threatening, lower respiratory tract infection.

Since 1996, the following two passive immunization techniques have been available: RSV IV immunoglobulins (Ig) (RSV-IGIV, RespiGam; Massachusetts Public Health Biological Laboratories; Boston, MA; and MedImmune, Inc; Gaithersburg, MD) and a humanized monoclonal antibody preparation against the F glycoprotein of RSV (palivizumab, Synagis; MedImmune, Inc). In controlled clinical trials, monthly prophylaxis during the RSV season reduced the hospitalization rate in the high-risk population. On the basis of these findings, in 1998 the American Academy of Pediatrics (AAP) recommended that RSV prophylaxis should be considered for the following patients:
1. Infants < 2 years old with CLD who warranted medical therapy (ie, supplemental oxygen, bronchodilators, diuretics, or corticosteroids) within 6 months before the anticipated RSV season;
2. Infants born at < 28 weeks of gestation who do not meet the first criterion, up to 12 months of age; and
3. Infants born at 29 to 32 weeks of gestation who do not meet the first criterion, up to 6 months of age.


Flu Treated by Drugs of My Canadian Pharmacy


The Essence of Flu

Flu is one of the most widespread infectious diseases, belongs to group of acute respiratory viral infections. Viruses of flu which more than 2000 types at the moment are cause this disease. These viruses can extend in the form of epidemics which rise, as a rule, on the autumn and winter period, and pandemics which are registered each 30-40 years.

People of all age categories are susceptible to flu virus, however this disease constitutes the greatest danger to elderly people, children, pregnant women, and also people having pulmonary diseases and cardiac disorders. A source of flu is already sick person who in environment allocates a virus by means of cough, sneezing and others. Being an airborne infection flu extends quickly enough, the patient represents danger to people around within a week, since the first hours of infection. Treat flu with My Canadian Pharmacy preparations.